Literature DB >> 15039330

Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells.

Carola Muñoz-Montesino1, Edilia Andrews, Rodolfo Rivers, Andrés González-Smith, Gustavo Moraga-Cid, Hugo Folch, Sandra Céspedes, Angel A Oñate.   

Abstract

In the development of vaccines capable of providing immunity against brucellosis, Cu-Zn superoxide dismutase (SOD) has been demonstrated to be one of the protective immunogens of Brucella abortus. In an earlier study, we provided strong evidence that intramuscular injection with a plasmid DNA carrying the SOD gene (pcDNA-SOD) was able to induce a protective immune response. The present study was designed to characterize T-cell immune responses after an intraspleen (i.s.) vaccination of BALB/c mice with pcDNA-SOD. Animals vaccinated with pcDNA-SOD did not develop SOD-specific antibodies, at least until week 4 after immunization (the end of the experiment), and in vitro stimulation of their splenocytes with either recombinant Cu-Zn SOD or crude Brucella protein induced the secretion of gamma interferon (IFN-gamma), but not interleukin-4, and elicited the induction of cytotoxic-T-lymphocyte activity. Upon analyzing the SOD-specific T-cell responses, the pcDNA-SOD vaccination was found to be stimulating both CD4(+)- and CD8(+)-T-cell populations. However, only the CD4(+) population was able to produce IFN-gamma and only the CD8(+) population was able to induce cytotoxic activity. Nevertheless, although i.s. route vaccination induces a significant level of protection in BALB/c mice against challenge with the virulent B. abortus strain 2308, vaccination by the intramuscular route with a similar amount of plasmid DNA does not protect. Based on these results, we conclude that i.s. immunization with pcDNA-SOD vaccine efficiently induced a Th1 type of immune response and a protective response that could be related to IFN-gamma production and cytotoxic activity against infected cells by SOD-specific CD4(+) and CD8(+) T cells, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039330      PMCID: PMC375181          DOI: 10.1128/IAI.72.4.2081-2087.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.

Authors:  A M Caruso; N Serbina; E Klein; K Triebold; B R Bloom; J L Flynn
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

3.  The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites.

Authors:  A Iwasaki; C A Torres; P S Ohashi; H L Robinson; B H Barber
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.

Authors:  G Widera; M Austin; D Rabussay; C Goldbeck; S W Barnett; M Chen; L Leung; G R Otten; K Thudium; M J Selby; J B Ulmer
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

5.  Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus.

Authors:  R Vemulapalli; S Cravero; C L Calvert; T E Toth; N Sriranganathan; S M Boyle; O L Rossetti; G G Schurig
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

6.  Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51.

Authors:  R Vemulapalli; Y He; S Cravero; N Sriranganathan; S M Boyle; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles.

Authors:  S C Chen; D H Jones; E F Fynan; G H Farrar; J C Clegg; H B Greenberg; J E Herrmann
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus.

Authors:  A A Oñate; R Vemulapalli; E Andrews; G G Schurig; S Boyle; H Folch
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope.

Authors:  S Casares; K Inaba; T D Brumeanu; R M Steinman; C A Bona
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

10.  DNA vaccination: transfection and activation of dendritic cells as key events for immunity.

Authors:  O Akbari; N Panjwani; S Garcia; R Tascon; D Lowrie; B Stockinger
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  19 in total

1.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  The superoxide dismutases of Bacillus anthracis do not cooperatively protect against endogenous superoxide stress.

Authors:  Karla D Passalacqua; Nicholas H Bergman; Amy Herring-Palmer; Philip Hanna
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

Review 3.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Construction of an expression plasmid (vector) encoding Brucella melitensis outer membrane protein, a candidate for DNA vaccine.

Authors:  Fatemeh Vahedi; Elnaz Ghorbani; Tahereh Falsafi
Journal:  Rep Biochem Mol Biol       Date:  2013-04

6.  An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice.

Authors:  Angel A Oñate; Gabriel Donoso; Gustavo Moraga-Cid; Hugo Folch; Sandra Céspedes; Edilia Andrews
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Authors:  Angello Retamal-Díaz; Roberto Riquelme-Neira; Darwin Sáez; Alejandra Rivera; Pablo Fernández; Alex Cabrera; Carlos A Guzmán; Angel Oñate
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

8.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 9.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

10.  Characterization of recombinant B. abortus strain RB51SOD toward understanding the uncorrelated innate and adaptive immune responses induced by RB51SOD compared to its parent vaccine strain RB51.

Authors:  Jianguo Zhu; Charles B Larson; Megan Ann Ramaker; Kimberly Quandt; Jered M Wendte; Kimberly P Ku; Fang Chen; George W Jourdian; Ramesh Vemulapalli; Gerhardt G Schurig; Yongqun He
Journal:  Front Cell Infect Microbiol       Date:  2011-11-25       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.